Table 3.

hTERT-related vaccines

NO	Vaccines	Level	Preclinical Model	Mechanism	Efficacy/Progress
1	RIAVAX	Clinical	Multiple cells	a. Induce anti-cancer T cells b. Enter into cancer cells and reduce HSP, HIF-1α and VEGF levels c. Inhibit angiogenesis	Help to treat prostate cancer, pancreas cancer, colorectal cancer, and malignant melanoma
2	UV1	Clinical	Multiple cells	Induce TERT-specific T cell and increase T cell activity	In combination with anti-PD1 therapies for the treatment of advanced malignant melanoma
3	GRNVAC1 and GRNVAC2	Clinical	Multiple cells	Expressed TERT in DCs allow them to present TERT-relative antigens	Help to treat Acute Myelogenous Leukemia
4	GX301	Clinical	Multiple cells	Induces TERT-specific T cell immunity	Help treating prostate and renal cancers
5	Vx-001	Clinical	HLA-A*0201 transgenic mouse	Induce and select TERT-specific T cells	Help treating NSCLC and advanced solid tumors